Deferasirox (ExJade): A Fluorescent Pro-Chelator Active Against Antibiotic Resistant Bacteria
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
Deferasirox, ExJade, an FDA-approved treatment for iron overload disorders has been shown to inhibit the growth of both gram-positive and -negative bacteria through iron (Fe(III)) chelation. Modification of the ExJade framework led to the identification of a new fluorescent platform ExPh and ExBT. Functionalization of the phenol moieties on ExBT with phosphate units afforded a ratiometric fluorescent pro-chelator (ExPhos), which was effective in the inhibition of two clinically relevant antibiotic-resistant bacteria, (MRSA (ATCC 43300) and VRE (ATCC 51299)), and allowed the fluorescent imaging of MRSA. Remarkably, this pro-chelation strategy proved selective towards bacteria with no cytotoxicity observed for ExPhos treated A549 cells (72 h incubation). This work represents a new pro-chelator antibiotic strategy that can be modified with a chosen reactive chemical trigger to provide a diagnostic signal in conjunction with a therapeutic response with a potential of minimal off-target toxicities.